Relapse after allogeneic hematopoietic cell therapy.

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Disease relapse is a primary cause of mortality post-allogeneic hematopoietic cell transplantation (HCT).
• Graft-versus-tumor/leukemia (GVT) effect biology is better understood, but relapse is influenced by conditioning, allograft type, and disease factors.
• Donor lymphocyte infusion (DLI) is standard for relapse treatment but shows variable efficacy based on disease histology and status.

Purpose of the Study:

• To address critical issues and research questions concerning relapse following allogeneic HCT.
• To explore novel therapies and strategies for managing HCT relapse.
• To improve outcomes for patients experiencing relapse after HCT, especially those unresponsive to or ineligible for DLI.

Main Methods:

• International workshop sponsored by the National Cancer Institute.
• Discussion and synthesis of current knowledge on HCT relapse.
• Identification of research gaps and future directions.

Main Results:

• Relapse post-HCT remains a major challenge with significant mortality.
• Current treatments like DLI have limitations in efficacy and applicability.
• A need exists for novel therapeutic approaches and preventative strategies.

Conclusions:

• Further research into the biology, natural history, prevention, and treatment of HCT relapse is crucial.
• Development of alternative or adjunct therapies to DLI is warranted.
• Collaborative efforts are essential to combat disease relapse after HCT.